We are pleased to acknowledge and thank our dedicated partners for their invaluable contributions to the successful completion of the In-Silico Validation phase of the CHAIMELEON Project. This critical milestone marked an important step in assessing the utility of the predictive AI models developed during the project.
The validation exercise, which has now been completed, was designed to evaluate how these AI models can support clinical decision-making. It consisted of two distinct stages, conducted over several months:
- Standard Clinical Evaluation: Cases were reviewed based solely on imaging and clinical data, with no AI support.
- AI-Augmented Case Review: The same cases were revisited, this time incorporating the AI predictions alongside the imaging and clinical data.
At the conclusion of the exercise, participants provided feedback through a brief survey, offering critical insights that will guide the ongoing refinement and development of AI tools for clinical use.
This milestone could not have been achieved without the expertise and collaboration of our partners. We extend our sincere gratitude to the following institutions for their crucial role in this effort:
- University Hospital G. Martino, Messina, Italy
- OSATEK, País Vasco, Spain
- Medipol University Hospital, Istanbul, Turkey
- Clinical Hospital Center, Rijeka, Croatia
- Vírgen del Rocío Hospital, Sevilla, Spain
- National Cancer Institute, Vilnius, Lithuania
Their dedication and commitment have been instrumental in advancing the CHAIMELEON Project’s vision of transforming healthcare through the integration of AI.
We look forward to continuing our collaboration as we further explore the potential of AI in clinical practice.
